# Dyne Therapeutics (DYN) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/DYN
## Company Profile
- Ticker: DYN
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: 25.88 USD
- Market cap: 2850009843.04 USD
- Last updated: 2026-08-06
## Business Overview
### Oligonucleotide Therapeutics
Dyne Therapeutics develops targeted oligonucleotide medicines for genetically driven muscle diseases. Its FORCE platform links therapeutic payloads to antibodies intended to improve delivery into muscle tissue.
### Duchenne Muscular Dystrophy
Z-rostudirsen is designed for patients with Duchenne muscular dystrophy amenable to exon 51 skipping. The candidate has completed the registrational portion of the DELIVER program, and Dyne is preparing it for regulatory submission and commercialization.
### Myotonic Dystrophy
Z-basivarsen targets toxic DMPK RNA in myotonic dystrophy type 1. It is being evaluated in the Phase 1/2 ACHIEVE study and the global confirmatory Phase 3 HARMONIA trial.
## Why The Stock Is Moving

As of Aug 6, 2026, DYN closed down 1.11% at $25.88. No new same-company headline was identified in the current news window.

## Future Catalysts

- BLA submission for z-rostudirsen in the second quarter of 2026.
- Completion of enrollment in the registrational ACHIEVE expansion cohort for z-basivarsen in the second quarter of 2026.
- Potential U.S. launch of z-rostudirsen in the first quarter of 2027, subject to approval.

## Recent News
- 2026-07-29 20:30 EST — [Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights](https://biopharmsignal.com/news/DYN/dyne-therapeutics-reports-second-quarter-2026-financial-results-and-recent-busin-f9e05f26) — Source: Dyne Therapeutics
- 2026-07-28 11:30 EST — [Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy (FSHD)](https://biopharmsignal.com/news/DYN/dyne-therapeutics-announces-u-s-fda-clearance-of-investigational-new-drug-ind-ap-634d2404) — Source: Dyne Therapeutics
- 2026-07-24 20:05 EST — [Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/DYN/dyne-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-b364d778) — Source: Dyne Therapeutics
- 2026-07-23 20:05 EST — [Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares](https://biopharmsignal.com/news/DYN/dyne-therapeutics-announces-closing-of-upsized-public-offering-of-common-stock-a-3a9bfff6) — Source: Dyne Therapeutics
- 2026-07-22 02:46 EST — [Dyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock](https://biopharmsignal.com/news/DYN/dyne-therapeutics-announces-pricing-of-upsized-375-million-public-offering-of-co-689996ee) — Source: Dyne Therapeutics